Legacy MEDSearch

JUNE 15, 2023

“At Cala, we’ve always been committed to expanding patient access and accelerating innovation in TAPS therapy for indications beyond essential tremor,” said Renee Ryan, CEO at Cala. “By By expanding into Parkinson’s disease, we are now able to bring this powerful treatment to additional patients who suffer from action hand tremors.”

Patients 98

Patients Recruitment Pharmacology Management 98

European Pharmaceutical Review

JULY 13, 2023

1,2 Moreover, except for countries such as Czechia, Denmark and Germany, the cost of these medications is borne by the patient, rather than national insurance or healthcare systems. This will lead to a higher proportion of these medicines becoming licensed, benefitting a larger number of patients. British journal of pharmacology.

Medical 98

Medical Food and Drug Administration Pharmacology Medicine 98

European Pharmaceutical Review

JANUARY 18, 2024

The company predicted this will be “driven by an increase in the patient share of dual orexin receptor antagonists (DORAs)”. Although the research noted that younger patients are increasingly switching from ERT to SRT, the current “familiarity” of existing therapies are expected to play a part in impeding the market’s expansion.

Marketing 98

Marketing Sales Pharmacology Pharma 98

Clarivate

SEPTEMBER 11, 2024

Approximately 43% of people with MCI develop dementia due to Alzheimer’s disease within 5 years (Roberts, 2014) (Figure 1). Personalized care relies on pharmacological and non-pharmacological interventions aimed at (temporarily) relieving cognitive and non-cognitive symptoms (Alzheimer’s Association, n.d.; Emblad, S.

Food and Drug Administration 59

Food and Drug Administration Pharmacology Food FDA 59